Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prednisone Treatment for Vestibular Neuronitis

This study has been completed.
Clalit Health Services, Haifa and West Galilee
Hillel Yaffe Medical Center
Rambam Health Care Campus
University Health Network, Toronto
Information provided by:
Carmel Medical Center Identifier:
First received: January 1, 2006
Last updated: November 4, 2007
Last verified: July 2007

The purpose of the study is to investigate the value of steroids in the treatment of vestibular neuronitis. The potential benefits of steroid therapy would be analyzed by the clinical response, self-perceived handicap and laboratory parameters.

Condition Intervention Phase
Vestibular Diseases
Vestibular Neuronitis
Drug: Prednisone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Prednisone Treatment for Vestibular Neuronitis

Resource links provided by NLM:

Further study details as provided by Carmel Medical Center:

Primary Outcome Measures:
  • Clinical: The presence of static and dynamic nystagmus, positional and positioning nystagmus, and disequilibrium on bedside examination. [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Functional: Scores on the Dizziness Handicap Inventory questionnaires. [ Time Frame: 12 months ]
  • Laboratory: Caloric lateralization and directional preponderance on electro-oculography (EOG). [ Time Frame: 12 months ]

Enrollment: 17
Study Start Date: September 2005
Study Completion Date: May 2007
Arms Assigned Interventions
Experimental: 1
Drug: Prednisone
PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
Other Name: Prednisone
Placebo Comparator: 2
Drug: Prednisone
PO, Placebo, 17 days

Detailed Description:

Vestibular neuronitis is the second most common cause of peripheral vestibulopathy (the first being benign paroxysmal positional vertigo) with incidence of about 3.5/100000. Currently vestibular neuronitis is explained by a viral pathogenesis.

Vestibular neuronitis is considered to have a benign course. The static rotatory vertigo and disequilibrium, present even when the patient is completely at rest, subside in most cases within a few days, and a gradual return to daily activities is the rule. However, it has been shown that there is generally incomplete restoration of peripheral function, and clinical recovery is achieved by proprioceptive and visual substitution for the unilateral vestibular deficit, combined with central vestibular compensation of the imbalance in vestibular tone. Although vestibular neuronitis is usually restricted to one attack, several studies have reported continuous or episodic vertigo or unsteadiness in 43% -53% of patients. The main residua include impaired vision and disequilibrium during walking and especially during head movement toward the affected ear. The rate of positive finding on vestibular evaluation may reach 60%. However, vestibular impairment as reflected by positive bedside testing and vestibular laboratory evaluation is not necessarily accompanied by subjective complaints and does not always reflect the level of incapacity.

The assumed HSV-1 etiology of vestibular neuronitis and the reported benefit of the combination of steroids and acyclovir in Bell's palsy suggest similar advantage in the treatment of vestibular neuronitis. Also, glucocorticoid receptors activation was reported to enhance vestibular compensation after acute peripheral vestibular insults in various animal models. A recent study investigated the effect of prednisolone versus valacyclovir and placebo on canal paresis in vestibular neuronitis patients. It was found that steroid treatment significantly improved peripheral vestibular function to the extent reflected by the caloric testing. However, bedside findings, patients' complaints and daily handicap were not evaluated. The relevance of the EOG caloric test results to clinical improvement could be argued in light of a previous report showing no correlation between EOG findings and residual symptoms in a long-term follow-up of vestibular neuronitis patients, and the finding that corticosteroid therapy had no effect on symptoms despite significant recovery of the caloric-test results.

The purpose of the study:

Prospective controlled longitudinal 12-month evaluation of the value of steroids in the treatment of vestibular neuronitis. The potential benefits of steroid therapy would be analyzed by the clinical response, self-perceived handicap and EOG laboratory parameters.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of vestibular neuronitis.
  • Documentation of unilateral reduced caloric response (caloric asymmetry >25%) on the EOG caloric study.

Exclusion Criteria:

  • Complaints of new hearing loss, tinnitus, or neurological deficits.
  • The presence of previously non-diagnosed sensorineural hearing loss (SNHL)
  • History of vestibular dysfunction.
  • Patient younger than 18 years of age.
  • Known contra-indication to systemic steroids: Unbalanced hypertension, un-controlled diabetes mellitus, immunodeficiency, active peptic disease, and avascular necrosis of the femoral head.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00271791

Unit of Otolaryngology Head and Neck Surgery, Hillel Yaffe Medical Center
Hadera, Israel, 38100
Department of Otolaryngology Head and Neck Surgery, Carmel Medical Center
Haifa, Israel, 34362
Department of Otolaryngology Head and Neck Surgery, Rambam Medical Center
Haifa, Israel, 31096
Otoneurolgy Unit, Lin Medical Center, Clalit Health Services
Haifa, Israel, 35152
Sponsors and Collaborators
Carmel Medical Center
Clalit Health Services, Haifa and West Galilee
Hillel Yaffe Medical Center
Rambam Health Care Campus
University Health Network, Toronto
Principal Investigator: Avi Shupak, MD Carmel Medical Center and Clalit Health Services, Haifa and West Galilee
Principal Investigator: Itzhak Braverman, MD Hillel Yaffe Medical Center
Principal Investigator: Avishai Golz, MD Rambam Health Care Campus
Principal Investigator: Elhanan Greenberg, ND Carmel Medical Center
Study Chair: Avi Shupak, MD Carmel Medical Center and Clalit Health Services, Haifa and West Galilee
  More Information

Publications: Identifier: NCT00271791     History of Changes
Other Study ID Numbers: 42352, 20050277
Study First Received: January 1, 2006
Last Updated: November 4, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Carmel Medical Center:
Vestibular Neuronitis
Vestibular Function Tests
Vestibular Adaptation

Additional relevant MeSH terms:
Guillain-Barre Syndrome
Vestibular Diseases
Vestibular Neuronitis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Cranial Nerve Diseases
Demyelinating Diseases
Ear Diseases
Immune System Diseases
Labyrinth Diseases
Nervous System Diseases
Neuromuscular Diseases
Otorhinolaryngologic Diseases
Peripheral Nervous System Diseases
Retrocochlear Diseases
Vestibulocochlear Nerve Diseases
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2014